1 – 8 of 8
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Effects of Recombinant α1-Microglobulin on Early Proteomic Response in Risk Organs after Exposure to 177Lu-Octreotate
- Contribution to journal › Article
- 2022
-
Mark
A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N
- Contribution to journal › Article
- 2021
-
Mark
Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment
- Contribution to journal › Article
- 2020
-
Mark
Tailoring Radionuclide Therapy of Neuroendocrine Tumors - Bridging the Gaps
(2020) In Lund University, Faculty of Medicine Doctoral Dissertation Series
- Thesis › Doctoral thesis (compilation)
- 2019
-
Mark
Protection of Kidney Function with Human Antioxidation Protein α
1
-Microglobulin in a Mouse
177
Lu-DOTATATE Radiation Therapy Model
- Contribution to journal › Article
- 2018
-
Mark
Inter-comparison of quantitative imaging of lutetium-177 (177Lu) in European hospitals
- Contribution to journal › Article
-
Mark
Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
- Contribution to journal › Article
- 2017
-
Mark
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
- Contribution to journal › Article
